NEW YORK – Regeneron Pharmaceuticals continues to advance commercial plans for Otarmeni (lunsotogene parvec), a gene therapy for an extremely rare type of genetic deafness. In the US, that includes an unprecedented agreement with the government to provide the treatment for free...
Continue Reading Here (Subscription Required): https://www.precisionmedicineonline.com/business-news/regenerons-otarmeni-gene-therapy-strategy-tests-new-pricing-approach
Subscribe to our mailing list for the latest insights on advanced therapy development, regulatory updates, industry trends, and upcoming events from Dark Horse Consulting Group.
We respect your privacy. Unsubscribe at any time. We will never sell your information.
